dupilumab

Overview

Dupilumab is a fully human monoclonal antibody used as a targeted therapy for type 2 inflammatory diseases. Its principal mechanism is blockade of interleukin-4 receptor alpha, which inhibits signaling by interleukin-4 and interleukin-13, two central cytokines in type 2 immune responses. By dampening this pathway, dupilumab reduces inflammatory activity that contributes to diseases such as atopic dermatitis, asthma, and eosinophilic esophagitis.

Clinically, dupilumab is notable for its broad use across multiple immune-mediated conditions driven by type 2 inflammation. Recent research continues to evaluate its effectiveness, safety, and comparative performance against other therapies, while also examining adverse effects such as ocular surface disease and eosinophilia. It is also being studied in special populations, including young children and patients with complex comorbid inflammatory disease.

Focus of Latest Publications

Recent publications demonstrate dupilumab's effectiveness across multiple type 2 inflammatory conditions in diverse clinical settings. In chronic spontaneous urticaria, a real-world multicentre cohort study of 51 patients showed that 69.7% achieved well-controlled disease at week 24, with response rates improving to 90.5% at week 52. Notably, dupilumab provided clinical benefit in most omalizumab-experienced patients, though prior nonresponders to omalizumab showed lower response rates (40% versus 85%). In eosinophilic esophagitis, real-world analysis of 336 patients across seven Austrian centres identified dupilumab in 12.2% of cases, predominantly as second-line therapy for patients with inadequate response to topical corticosteroids (59%) or intolerant to standard treatments (24%); 97.6% of dupilumab-treated patients remained on therapy at final follow-up.

Dupilumab's clinical utility extends to challenging settings including immune checkpoint inhibitor-induced bullous pemphigoid, where 94.74% of 19 patients achieved clinical response with 84.21% attaining complete remission. Among these patients, 82.35% discontinued systemic corticosteroids following dupilumab initiation, and notably, 61.11% were able to continue or reintroduce checkpoint inhibitor therapy—an important consideration for preserving oncological outcomes. In pediatric populations, dupilumab demonstrates safety and efficacy in severe atopic dermatitis across infants and young children (6 months to 5 years), and extends to atopic dermatitis and eosinophilic esophagitis in pediatric liver transplant recipients, conditions arising from tacrolimus-induced T helper 2 cell predominance.

Beyond clinical response, real-world studies provide mechanistic and comparative insights. In atopic dermatitis patients treated with dupilumab, seasonal variation in immune responses persists despite IL-4/IL-13 blockade; winter months showed elevated stimulated interferon-gamma, tumor necrosis factor-alpha, interleukin-2, and interleukin-6, indicating preserved inducible TH1 and innate immune activity. Comparisons with upadacitinib reveal distinct tolerability profiles: while dupilumab is associated with ocular surface disease, JAK inhibitors may present a more favorable ocular safety profile. Dupilumab was well tolerated across indications, with predominantly mild adverse events reported; treatment durability remained high in real-world populations, with most patients continuing therapy when clinical response was achieved. These findings collectively support dupilumab's role as an effective maintenance therapy for multiple type 2 inflammatory conditions, particularly in treatment-refractory populations and specialized clinical contexts.